oksaliplatin sandoz 5 mg/ml koncentrat za raztopino za infundiranje
ebewe pharma - oksaliplatin - koncentrat za raztopino za infundiranje - oksaliplatin 5 mg / 1 ml - oksaliplatin
oxamed 5 mg/ml prašek za raztopino za infundiranje
prašek za raztopino za infundiranje - oksaliplatin
oksaliplatin sandoz 5 mg/ml koncentrat za raztopino za infundiranje
ebewe pharma - oksaliplatin - koncentrat za raztopino za infundiranje - oksaliplatin 5 mg / 1 ml - oksaliplatin
oksaliplatin sandoz 5 mg/ml koncentrat za raztopino za infundiranje
ebewe pharma - oksaliplatin - koncentrat za raztopino za infundiranje - oksaliplatin 5 mg / 1 ml - oksaliplatin
oxamed 5 mg/ml prašek za raztopino za infundiranje
prašek za raztopino za infundiranje - oksaliplatin
oxamed 5 mg/ml prašek za raztopino za infundiranje
prašek za raztopino za infundiranje - oksaliplatin
lonsurf
les laboratoires servier - trifluridine, tipiracil hidroklorid - kolorektalne neoplazme - antineoplastična sredstva - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
vectibix
amgen europe b.v. - panitumumab - kolorektalne neoplazme - antineoplastična sredstva - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. v drugi vrstici v kombinaciji z folfiri za bolnike, ki so prejeli prvo linijo fluoropyrimidine, ki temelji kemoterapijo (razen irinotecan). kot monotherapy po okvari fluoropyrimidine-, oxaliplatin-in irinotecan, ki vsebujejo kemoterapijo regimens.
oksaliplatin ebewe 5 mg/ml prašek za raztopino za infundiranje
ebewe pharma - oksaliplatin - prašek za raztopino za infundiranje - oksaliplatin 5 mg / 1 ml - oksaliplatin
oksaliplatin kabi 5 mg/ml koncentrat za raztopino za infundiranje
fresenius kabi austria gmbh. - oksaliplatin - koncentrat za raztopino za infundiranje - oksaliplatin 5 mg / 1 ml - oksaliplatin